<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061032</url>
  </required_header>
  <id_info>
    <org_study_id>IHN10002</org_study_id>
    <nct_id>NCT03061032</nct_id>
  </id_info>
  <brief_title>Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients</brief_title>
  <acronym>HepCC-2</acronym>
  <official_title>Open-label Study of Efficacy and Safety of Generic Sofosbuvir/LedipasvirÂ±Ribavirin in Iranian Patients With Hepatitis C Virus Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iran Hepatitis Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Iran Hepatitis Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C virus (HCV) infection with around 0.5% and 2.2% prevalence in Iran and world is
      one of the public health problems resulting in chronic liver disease, cirrhosis and
      hepatocellular carcinoma. All cases of chronic HCV infections are candidates of treatment to
      prevent advanced liver diseases. The previous Pegylated-interferon and Ribavirin therapy was
      not efficient in all cases and results in numerous number of side-effects. Introduction of
      direct acting antiviral agents (DAAs) such as Sofosbuvir and Ledipasvir make the eradication
      of HCV possible however these regimens are not affordable and available in developing
      countries. The generic DAAs are manufactured in many of these countries such as Iran to
      provide the treatment with reasonable price.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>12 weeks after completion of treatment</time_frame>
    <description>Undetectable HCV RNA 12 weeks after completion of treatment with RT-PCR or TMA with a 15 IU/mL limit of detection</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir/Ledipasvir for 12W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients without cirrhosis and previous history of treatment will be treated with this regimen.
Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir/Ledipasvir+Ribavirin for 12W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.
Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir/Ledipasvir for 24W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.
Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir/Ledipasvir+Ribavirin for 24W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/Ledipasvir 12W</intervention_name>
    <description>Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.</description>
    <arm_group_label>Sofosbuvir/Ledipasvir for 12W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/Ledipasvir plus Ribavirin 12W</intervention_name>
    <description>Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.</description>
    <arm_group_label>Sofosbuvir/Ledipasvir+Ribavirin for 12W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/Ledipasvir 24W</intervention_name>
    <description>Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.</description>
    <arm_group_label>Sofosbuvir/Ledipasvir for 24W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/Ledipasvir plus Ribavirin 24W</intervention_name>
    <description>Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.</description>
    <arm_group_label>Sofosbuvir/Ledipasvir+Ribavirin for 24W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV infection

          -  &gt;18 years old

        Exclusion Criteria:

          -  HIV co-infected

          -  Liver transplanted

          -  Receiving drugs with suspected interactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seyed Moayed Alavian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Iran Hepatitis Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heidar Sharafi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Iran Hepatitis Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bita Behnava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iran Hepatitis Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Saeid Rezaee-Zavareh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iran Hepatitis Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seyed Moayed Alavian, MD</last_name>
    <phone>+989121073195</phone>
    <email>alavian@thc.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidar Sharafi, PhD</last_name>
    <phone>+989125176030</phone>
    <email>h.sharafi@meldcenter.com</email>
  </overall_contact_backup>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 17, 2017</last_update_submitted>
  <last_update_submitted_qc>February 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

